Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) traded up 10.4% on Tuesday . The stock traded as high as $14.65 and last traded at $14.00, with a volume of 1,183,761 shares changing hands. The stock had previously closed at $12.68.

AQXP has been the subject of several research analyst reports. Jefferies Group raised their target price on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research report on Friday, August 5th. Zacks Investment Research cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $22.00 target price on shares of Aquinox Pharmaceuticals in a research report on Wednesday, August 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $19.86.

The firm’s market capitalization is $233.05 million. The stock’s 50-day moving average price is $10.49 and its 200 day moving average price is $8.62.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/aquinox-pharmaceuticals-inc-aqxp-trading-10-4-higher.html

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.22. Equities analysts anticipate that Aquinox Pharmaceuticals Inc. will post ($2.11) earnings per share for the current year.

A number of large investors have recently made changes to their positions in AQXP. Bank of Montreal Can acquired a new stake in shares of Aquinox Pharmaceuticals during the second quarter valued at $166,000. Bridgeway Capital Management Inc. boosted its position in Aquinox Pharmaceuticals by 416.7% in the second quarter. Bridgeway Capital Management Inc. now owns 62,000 shares of the company’s stock worth $410,000 after buying an additional 50,000 shares during the period. BlackRock Inc. boosted its position in Aquinox Pharmaceuticals by 24.3% in the first quarter. BlackRock Inc. now owns 50,600 shares of the company’s stock worth $446,000 after buying an additional 9,900 shares during the period. Geode Capital Management LLC boosted its position in Aquinox Pharmaceuticals by 21.8% in the first quarter. Geode Capital Management LLC now owns 62,949 shares of the company’s stock worth $555,000 after buying an additional 11,268 shares during the period. Finally, Vanguard Group Inc. boosted its position in Aquinox Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 110,529 shares of the company’s stock worth $731,000 after buying an additional 2,197 shares during the period. Institutional investors own 89.41% of the company’s stock.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

5 Day Chart for NASDAQ:AQXP

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.